BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology

News   Nov 14, 2007

 
BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
 
 
 

RELATED ARTICLES

Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell Types

News

New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.

READ MORE

Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing Organization

News

Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..

READ MORE

BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences Products

News

BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE